...
首页> 外文期刊>International journal of gynecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics >Fetal and neonatal outcomes after term and preterm delivery following betamethasone administration in twin pregnancies
【24h】

Fetal and neonatal outcomes after term and preterm delivery following betamethasone administration in twin pregnancies

机译:倍他米松双胎妊娠足月和早产后的胎儿和新生儿结局

获取原文
获取原文并翻译 | 示例
           

摘要

Objective: To investigate effects of betamethasone on fetal growth and neonatal outcomes in twins. Methods: A retrospective cohort study was conducted of twins delivered at one center in Berlin, Germany, between 1993 and 2011. The betamethasone group included twin pregnancies with preterm labor, cervical shortening, preterm premature rupture of membranes, or vaginal bleeding, and exposure to betamethasone between 23(+5) and 33(+6) weeks. The control group included twin pregnancies with no betamethasone exposure matched for length at delivery. Fetal growth and neonatal anthropometric data were analyzed by twin-pair structure, dose, and gestational age (linear mixed model). Results: Overall, 1922 live-born twin pairs (653 betamethasone group, 1269 controls) were included. Compared with controls, late-preterm twins exposed to betamethasone were lighter (mean difference -126 g), had a smaller head circumference (-0.4 cm), and a shorter body length (-0.8 cm) after adjustment for confounders (P < 0.05). Female neonates from mixed or same-sex twin pairs had a lower birth weight than controls (betamethasone <= 16 mg: -114 g; betamethasone 24 mg: -124 g; betamethasone >24 mg: -187 g), with no detectable improvement in neonatal morbidity (hyperbilirubinemia, respiratory distress, asphyxia) or mortality. Conclusion: Betamethasone reduced birth weight, head circumference, and length of female preterm neonates in twin pairs in a dose-dependent manner. The neonatal mortality and morbidity were not improved by betamethasone. (C) 2016 International Federation of Gynecology and Obstetrics. Published by Elsevier Ireland Ltd. All rights reserved.
机译:目的:研究倍他米松对双胞胎胎儿生长和新生儿结局的影响。方法:对1993年至2011年在德国柏林的一个中心分娩的双胞胎进行了一项回顾性队列研究。倍他米松组包括双胎妊娠,早产,子宫颈缩短,胎膜早破或阴道流血以及暴露于倍他米松在23(+5)到33(+6)周之间。对照组包括双胎妊娠,没有倍他米松暴露与分娩时长相匹配。通过双对结构,剂量和胎龄(线性混合模型)分析胎儿的生长和新生儿人体测量数据。结果:总共包括1922活产双胞胎(653个倍他米松组,1269个对照组)。与对照组相比,暴露于倍他米松的早产双胞胎更轻(平均差异为-126 g),调整混杂因素后头围较小(-0.4 cm),体长较短(-0.8 cm)(P <0.05) )。混合或同性双胞胎对的新生儿的出生体重比对照组低(倍他米松<= 16毫克:-114克;倍他米松24毫克:-124克;倍他米松> 24毫克:-187克),无可检测的改善新生儿发病率(高胆红素血症,呼吸窘迫,窒息)或死亡率。结论:倍他米松以剂量依赖的方式降低了双胞胎对的早产儿的出生体重,头围和身长。倍他米松未改善新生儿的死亡率和发病率。 (C)2016国际妇产科联合会。由Elsevier Ireland Ltd.发布。保留所有权利。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号